Chronic Cardiovascular and Kidney Disorder (CCKD) represents a growing challenge in healthcare, characterized by the complex interplay between heart and kidney diseases. This manuscript delves into the “butterfly effect” in CCKD, a phenomenon in which acute injuries in one organ lead to progressive dysfunction in the other. Through extensive review, we explore the pathophysiology underlying this effect, emphasizing the roles of acute kidney injury (AKI) and heart failure (HF) in exacerbating each other. We highlight emerging therapies, such as renin–angiotensin–aldosterone system (RAAS) inhibitors, SGLT2 inhibitors, and GLP1 agonists, that show promise in mitigating the progression of CCKD. Additionally, we discuss novel therapeutic targets, including Galectin-3 inhibition and IL33/ST2 pathway modulation, and their potential in altering the course of CCKD. Our comprehensive analysis underscores the importance of recognizing and treating the intertwined nature of cardiac and renal dysfunctions, paving the way for more effective management strategies for this multifaceted syndrome.
Kidney transplantation remains the best treatment for chronic kidney failure, offering better outcomes and quality of life compared with dialysis. Cardiovascular disease (CVD) is a major cause of morbidity and mortality in kidney transplant recipients and is associated with decreased patient survival and worse graft outcomes. Post-transplant CVD results from a complex interaction between traditional cardiovascular risk factors, such as hypertension and diabetes, and risk factors specific to kidney transplant recipients including chronic kidney disease, immunosuppressive drugs, or vascular access. An accurate assessment of cardiovascular risk is now needed to optimize the management of cardiovascular comorbidities through the detection of risk factors and the screening of hidden pretransplant coronary artery disease. Promising new strategies are emerging, such as GLP-1 receptor agonists and SGLT2 inhibitors, with a high potential to mitigate cardiovascular complications, although further research is needed to determine their role in kidney transplant recipients. Despite this progress, a significant gap remains in understanding the optimal management of post-transplant CVD, especially coronary artery disease, stroke, and peripheral artery disease. Addressing these challenges is essential to improve the short- and long-term outcomes in kidney transplant recipients. This narrative review aims to provide a comprehensive overview of cardiovascular risk assessment and post-transplant CVD management.
6 June 2025 in American Journal of Transplantation
Cardiovascular disease remains a major cause of morbidity and mortality in kidney transplant recipients. This multicenter cohort study examined the association between delayed graft function (DGF) and major adverse cardiovascular events (MACE) in a cohort of 18,149 kidney transplant recipients from 17 French hospitals, transplanted between 2008 and 2022. The primary outcome measured was the incidence of MACE, including cardiovascular death, coronary artery disease, heart failure, and stroke, with secondary outcomes of graft failure and non-cardiovascular death. Among the cohort, 4,182 (23.0%) experienced DGF, which was associated with a significantly increased risk of MACE (HR: 1.24, 95% CI: 1.10-1.40), particularly coronary artery disease, heart failure, and cardiovascular death, but not stroke. The association of DGF with an increased MACE incidence remained consistent over time (interaction p-value = 0.19) and intensified with greater DGF severity, as measured by the number of dialysis sessions required after transplantation (p for trend = 0.01). Graft function did not significantly mediate the association between DGF and MACE (p = 0.62). These findings suggest that the renal lesions resulting from DGF may mediate cardiovascular risk, highlighting the need for optimized prevention and treatment strategies to improve patient outcomes.